Patents Examined by Rebecca E. Prouty
  • Glyphosate-N-acetyltransferase (GAT) genes
    Patent number: 7527955
    Abstract: Novel proteins are provided herein, including proteins capable of catalyzing the acetylation of glyphosate and other structurally related proteins. Also provided are novel polynucleotides capable of encoding these proteins, compositions that include one or more of these novel proteins and/or polynucleotides, recombinant cells and transgenic plants comprising these novel compounds, diversification methods involving the novel compounds, and methods of using the compounds. Some of the novel methods and compounds provided herein can be used to render an organism, such as a plant, resistant to glyphosate.
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: May 5, 2009
    Assignees: Pioneer Hi-Bred International, Inc., Verdia, Inc.
    Inventors: Linda A. Castle, Dan Siehl, Lorraine Giver, Jeremy Minshull, Cristina Ivy, Yong Hong Chen, Nicholas B. Duck, Phillip A. Patten
  • Signal peptide for producing a polypeptide
    Patent number: 7527947
    Abstract: The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: May 5, 2009
    Assignee: Novozymes A/S
    Inventors: Tomoko Matsui, Henriette Draborg, Steffen Danielsen
  • Methods and compositions for vitamin K epoxide reductase
    Patent number: 7524665
    Abstract: The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: April 28, 2009
    Assignee: University of North Carolina at Chapel Hill
    Inventors: Darrel W. Stafford, Tao Li
  • Method for diversifying the chemical composition of proteins produced in vivo by genetically disabling the editing function of their aminoacyl tRNA synthetases
    Patent number: 7524646
    Abstract: The present invention is directed to a method to diversify the chemical composition of proteins produced in vivo comprising the step of disabling, particularly by mutagenesis, the editing function of one of its aminoacyl tRNA synthetases. The present invention is also directed to nucleic acid sequences encoding such mutated aminoacyl tRNA synthetases having their editing site mutated and capable of mischarging its cognate tRNA with a noncanonical amino acid. Also described herein is an improved method for obtaining transformed cells capable of synthetizing in vivo proteins comprising at least a noncanonical amino acid and their use for the production of such proteins.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: April 28, 2009
    Assignees: Institut Pasteur, The Scripps Research Institute, Evologic GmbH
    Inventors: Volker Doring, Leslie A. Nangle, Tamara L. Hendrickson, Valerie De Crecy-Lagard, Paul Schimmel, Philippe Marliere
  • strain CYL1892
    Patent number: 7521221
    Abstract: This disclosure presents embodiments of novel strains of Staphylococcus aureus that through genetic engineering produce type 5 capsular polysaccharide at greater levels than Staphylococcus aureus strain Reynolds.
    Type: Grant
    Filed: November 21, 2005
    Date of Patent: April 21, 2009
    Assignee: Board of Trustees of the University of Arknasas
    Inventors: Chia Y. Lee, Thanh T. Luong
  • Method for protein production
    Patent number: 7517678
    Abstract: Provided is a novel comprising culturing host cells into which a foreign gene has been introduced for producing a protein in a soluble form encoded by the foreign gene, recombinant cells are cultured in the temperature range lower than or equal to the upper temperature limit for growth of the host cells and higher than 5 degrees below the upper temperature limit for growth of the host cells after induction of expression.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: April 14, 2009
    Assignees: Waseda University, Chisso Corporation
    Inventors: Daisuke Koma, Kuniki Kino, Toshiya Sawai
  • ADAMTS13 genes and proteins and variants and therapeutic compositions and methods utilizing the same
    Patent number: 7517522
    Abstract: The present invention relates to a disintegrin and metalloproteinase containing thrombospondin 1-like domains (ADAMTS) and in particular to a novel ADAMTS13 protease and to nucleic acids encoding ADAMTS13 proteases. The present invention encompasses both native and recombinant wild-type forms of ADAMTS13, as well as mutant and variant forms including fragments, some of which posses altered characteristics relative to the wild-type ADAMTS13. The present invention also relates to methods of using ADAMTS13, including for treatment of TTP. The present invention also relates to methods for screening for the presence of TTP. The present invention further relates to methods for developing anticoagulant drugs based upon ADAMTS13.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: April 14, 2009
    Assignee: The Regents of the University of Michigan
    Inventors: David Ginsburg, Gallia Levy, Han-Mou Tsai
  • Plant-derived alkaline alpha-galactosidase
    Patent number: 7514254
    Abstract: There are provided novel plant-derived enzymes for hydrolysis of sugars and particularly an alkaline alpha-galactosidase which hydrolyzes a broad spectrum of galactosyl-saccharides such as melibiose, raffinose and stachyose and guar gum, at neutral to alkaline pH conditions.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: April 7, 2009
    Assignee: The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center
    Inventors: Arthur A. Schaffer, Gao Zhifang
  • IRAK 1c splice variant and its use
    Patent number: 7510858
    Abstract: IRAK 1c [Interleukin-1 Receptor-Associated Kinase 1c] splice variants and their preparation and use are described. The splice variants may be used in drug screening assays and methods for diagnosing medical conditions mediated by IRAK 1c-modulating activity.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: March 31, 2009
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Wai-Ping Leung, Navin Rao
  • Thermostable cellulase and methods of use
    Patent number: 7510857
    Abstract: A Clostridium thermocellum thermostable cellulase enzyme with both endocellulase activity and exocellulase activity that is able to degrade cellulose in the absence of scaffolding and other cellulosomic proteins is provided. The use of the enzyme to degrade cellulosic materials to soluble sugars is also provided.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: March 31, 2009
    Assignee: C5-6 Technologies, Inc.
    Inventor: Phillip Brumm
  • Xylanases with enhanced thermophilicity and alkalophilicity
    Patent number: 7510860
    Abstract: The present invention provides a xylanase, or a modified xylanase enzyme comprising at least one substituted amino acid residue at a position selected from the group consisting of amino acid 11, 116, 118, 144 and 161, the position determined from sequence alignment of the modified xylanase with Trichoderma reesei xylanase II amino acid sequence. The xylanases described herein exhibit improved thermophilicity, alkalophilicity, expression efficiency, or a combination thereof, in comparison to a corresponding native xylanase.
    Type: Grant
    Filed: November 21, 2001
    Date of Patent: March 31, 2009
    Assignee: National Research Council of Canada
    Inventor: Wing L. Sung
  • Subtilisin variants with improved perhydrolase activity
    Patent number: 7510859
    Abstract: The invention relates to novel perhydrolases, derived from the protease Carlsberg by amino acid exchange in positions 11, 15, 21, 38, 50, 54, 58, 77, 83, 89, 93, 96, 107, 117, 120, 134, 135, 136, 140, 147, 150, 154, 155, 160, 161, 171, 179, 180, 181, 194, 205, 208, 213, 216, 217, 238, 239, 251, 253, 257, and/or 261. The invention further relates to methods for production of said novel perhydrolases, products comprising said novel perhydrolases, particularly bodycare, haircare, shampoo, hair-dyeing, hair-bleaching, oral-care, dental-dare, dental-prosthesis-care, cosmetic, therapeutic (textile) washing, cleaning, rinsing, handwash, washing-up and dish-washing products, and corresponding applications of said novel perhydrolases.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: March 31, 2009
    Assignee: Henkel Kommanditgesellschaft Auf Aktien
    Inventors: Susanne Wieland, Laura Polanyi-Bald, Inken Prueser, Regina Stehr, Karl-Heinz Maurer
  • Catalytic anti-factor VIII allo-antibodies
    Patent number: 7507540
    Abstract: A method is disclosed of determining the presence of catalytic anti-Factor VIII allo-antibodies capable of degrading Factor VIII in a mammal, and of characterising the cleavage sites in said Factor VIII molecule by said catalytic anti-Factor VIII allo-antibodies. It also relates to an anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor; and to a pharmaceutical composition comprising said catalytic anti-Factor VIII allo-antibodies which are capable of degrading Factor VIII and which originate from said method of determination; and further to a pharmaceutical composition comprising said anti-Factor VIII allo-antibody-catalysed Factor VIII degradation inhibitor.
    Type: Grant
    Filed: July 18, 2000
    Date of Patent: March 24, 2009
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Bayer Pharma
    Inventors: Srinivas Kaveri, Sébastien Lacroix-Desmazes, Michel Kazatchkine
  • Recombinant chondroitinase ABC I and uses thereof
    Patent number: 7507570
    Abstract: The invention relates to chondroitinase ABC I and uses thereof. In particular, the invention relates to recombinant and modified chondroitinase ABC I, their production and their uses. The chondroitinase ABC I enzymes of the invention are useful for a variety of purposes, including degrading and analyzing polysaccharides such as glycosaminoglycans (GAGs). These GAGs can include chondroitin sulfate, dermatan sulfate, unsulfated chondroitin and hyaluronan. The chondroitinase ABC I enzymes can also be used in therapeutic methods such as promoting nerve regeneration, promoting stroke recovery, treating spinal cord injury, treating epithelial disease, treating infections and treating cancer.
    Type: Grant
    Filed: March 10, 2005
    Date of Patent: March 24, 2009
    Assignee: Massachusetts Institute of Technology
    Inventors: Vikas Prabhakar, Ishan Capila, Rahul Raman, Carlos Bosques, Kevin Pojasek, Ram Sasisekharan
  • Method for producing ?-hydroxy amino acid and enzyme used therefor
    Patent number: 7507559
    Abstract: A method for producing ?-hydroxy amino acid and its optically-active isomer is provided. The ?-hydroxy amino acid is produced by reacting a predetermined D-?-amino acid and 5,10-methylene tetrahydrofolic acid in the presence of an enzyme derived from a microorganism belonging to the genera Paracoccus, Aminobacter, or Ensifer.
    Type: Grant
    Filed: May 22, 2006
    Date of Patent: March 24, 2009
    Assignee: Ajinomoto Co., Inc.
    Inventors: Hiroyuki Nozaki, Shinji Kuroda, Kunihiko Watanabe, Kenzo Yokozeki
  • Kallikrein gene
    Patent number: 7507403
    Abstract: The invention relates to a kallikrein protein, compositions comprising the protein, and the use thereof.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: March 24, 2009
    Assignee: Mount Sinai Hospital
    Inventors: George M. Yousef, Eleftherios P. Diamandis
  • Variant subtilisin enzymes (subtilases)
    Patent number: 7507569
    Abstract: Novel subtilases having an improved wash performance on egg stains are disclosed. These subtilases are useful exhibiting excellent or improved wash performance on egg stains when used in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dish wash compositions, including automatic dish wash compositions.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: March 24, 2009
    Assignees: Novozymes A/S, Maxygen Inc.
    Inventors: Stefan Minning, Jurgen Carsten Franz Knotzel, Niels Henrik Sorensen, Jon E. Ness, Mark D. Welch, Lorraine J. Giver, Joel Cherry, Torben Vedel Borchert, Jeremy Minshull
  • Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)
    Patent number: 7507717
    Abstract: An isolated, synthetic or recombinant X-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO:3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not MrIA, MrIB, Mar2, CMrVIA, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof.
    Type: Grant
    Filed: December 2, 2003
    Date of Patent: March 24, 2009
    Assignee: Xenome Ltd.
    Inventors: Richard James Lewis, Paul Francis Alewood, Dianne Alewood, Elka Palant
  • Methods of producing prenyl alcohols
    Patent number: 7501268
    Abstract: A method of producing a prenyl alcohol, comprising creating a recombinant by transferring into a host a recombinant DNA for expression or a DNA for genomic integration each comprising a prenyl diphosphate synthase gene or a mutant thereof, culturing the resultant recombinant, and recovering the prenyl alcohol from the resultant culture.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: March 10, 2009
    Assignee: Toyota Jidosha Kabushiki Kaisha
    Inventors: Chikara Ohto, Shusei Obata, Masayoshi Muramatsu, Kiyohiko Nishi, Kazuhiko Totsuka
  • Human cytoplasmic polyadenylation element binding protein and uses thereof
    Patent number: 7501249
    Abstract: The present invention provides genomic and cDNA encoding human cytoplasmic polyadenylation element binding protein, expression vectors comprising human cytoplasmic polyadenylation element binding protein cDNA and host cells that contain the expression vectors. Also provided are recombinant human cytoplasmic polyadenylation element binding protein and polypeptides derived thereof. In addition, the present invention reports that the human Mos 3? untranslated region (3? UTR) contains a functional cytoplasmic polyadenylation element (CPE), interacts with the human CPEB1 protein and directs maturation-dependent cytoplasmic polyadenylation of the endogenous Mos mRNA.
    Type: Grant
    Filed: November 15, 2005
    Date of Patent: March 10, 2009
    Inventor: Angus M. MacNicol